Plain-English translation of NCT06769113 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to treat people with advanced esophageal squamous cell carcinoma (a type of esophageal cancer) whose cancer has returned or spread after standard first-line treatments. The study will test three different doses of the medication given by IV infusion every three weeks to see which dose works best and how safe it is. This is a Phase II trial, meaning it's moved beyond early safety testing and is now focused on whether the treatment is effective.
People whose esophageal cancer comes back after standard chemotherapy and immunotherapy treatments need new options. This medication is being studied because it combines two approaches to fight cancer in a way that may help patients whose tumors are no longer responding to current treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of three doses of the medication, given as an intravenous infusion every three weeks. You'll need to complete regular visits for infusions, blood tests, and imaging scans to monitor how your cancer is responding and track any side effects. The study involves about 102 participants total, and you'll be closely followed to help researchers understand the best dose and how well this treatment works for your type of cancer.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Shanghai Henlius Biotech
Enrollment target
~102 participants
Started
January 2025
Primary completion
October 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jinming Yu, Dr.
Shandong Cancer Hospital and Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.